News

DSM looks to improve results in 2015

DSM has reported 2014 sales of €9,181 million, 4% up on the prior year reflecting organic sales growth of 5% in Q4 2014 and 3% for 2014. Q4 2014 EBITDA was €288 million with full year EBITDA of €1,168 million, in line with market expectations. The company said it will take further actions to improve […]

DSM has reported 2014 sales of €9,181 million, 4% up on the prior year reflecting organic sales growth of 5% in Q4 2014 and 3% for 2014. Q4 2014 EBITDA was €288 million with full year EBITDA of €1,168 million, in line with market expectations.

The company said it will take further actions to improve efficiencies and to reduce costs, aiming to deliver a 2015 EBITDA slightly ahead of 2014

“DSM generated 3% organic growth and delivered a relatively solid EBITDA with good cash flow from operating activities, amongst others due to improved operating working capital management,” said Feike Sijbesma, CEO/Chairman of the DSM Managing Board. “This was achieved despite the fact that 2014 was not an easy year for DSM with substantial negative exchange rate effects and tough market conditions in Nutrition and caprolactam. DSM is already taking steps to address the challenging external environment. We will continue to focus on operational performance and this will be complemented by accelerated actions to improve efficiencies and reduce costs, specifically in Nutrition and across all functions in the company.”